Abstract: An example apparatus having a first and second data terminal and including a first transistor having a first terminal, a second terminal, and a control terminal; a second transistor having a first terminal and a control terminal, the first terminal of the second transistor coupled to the first terminal of the first transistor; a third transistor having a first terminal, a second terminal, and a control terminal; a fourth transistor having a first terminal and a control terminal, the first terminal of the fourth transistor coupled to the first terminal of the third transistor; and gate driver circuitry having a first terminal, and a second terminal, the first terminal of the gate driver circuitry coupled to the first data terminal, and the second terminal of the first transistor, the second terminal of the gate driver circuitry coupled to the second data terminal and the second terminal of third transistor.

Abstract: Systems and methods are provided for facilitating the management of AI (artificial intelligence) agents, AI agent skills, and customer access to AI agents and AI agent skills. Systems identify an AI agent and AI agent skills that the AI agent can utilize when interacting with different customers. The systems also identify a plurality of customers that the AI agent is capable of interacting with while utilizing one or more of the AI agent skills. The systems also generate and display interfaces that identify the plurality of customers with interactive permission controls for selectively enabling and/or disabling AI agent interactions by the AI agent the corresponding customers.

Abstract: An example apparatus having a first and second data terminal and including a first transistor having a first terminal, a second terminal, and a control terminal; a second transistor having a first terminal and a control terminal, the first terminal of the second transistor coupled to the first terminal of the first transistor; a third transistor having a first terminal, a second terminal, and a control terminal; a fourth transistor having a first terminal and a control terminal, the first terminal of the fourth transistor coupled to the first terminal of the third transistor; and gate driver circuitry having a first terminal, and a second terminal, the first terminal of the gate driver circuitry coupled to the first data terminal, and the second terminal of the first transistor, the second terminal of the gate driver circuitry coupled to the second data terminal and the second terminal of third transistor.

Abstract: Provided are novel anti-SEZ6 antibodies and antibody drug conjugates, and methods of using such anti-SEZ6 antibodies and antibody drug conjugates to treat cancer.

Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.

Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.

Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.

Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.

Abstract: Various embodiments are described herein for a device and method for interacting with customers on e-commerce platforms. The various embodiments described herein generally relate to methods and apparatus for interacting with customers. In one embodiment, the system may be used in conjunction with e-commerce platforms, electronic document platforms, and any other electronic platforms. In other embodiments, the interaction with customers can be on electronic documents, portable document formats (PDFs), email and other forms of electronic platforms. On e-commerce platforms, customers can use electronic devices such as laptops, tablets, and mobile devices to browse products before deciding to make a purchase decision.

Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of a4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.

Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Abstract: An electronic device, method, and computer readable medium for an invertible wavelet layer for neural networks are provided. The electronic device includes a memory and at least one processor coupled to the memory. The at least one processor is configured to receive an input to a neural network, apply a wavelet transform to the input at a wavelet layer of the neural network, and generate a plurality of subbands of the input as a result of the wavelet transform.

Abstract: Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.

Abstract: Provided herein are mutant interleukin-10 polypeptides, and fusion polypeptides comprising the mutant interleukin-10 polypeptides and antigen binding molecules. The present disclosure provides methods of modulating immune cell function by contacting the immune cell with fusion polypeptides of the present disclosure. In addition, the disclosure also provides polynucleotides encoding the disclosed fusion molecules, and vectors and host cells comprising such polynucleotides. The present disclosure further provides methods for producing the fusion molecules, pharmaceutical compositions comprising the same, and uses thereof.

Abstract: A demand-based load balancing function may be provided by one or more drive controllers that takes advantage of the affinity laws to linearize the control of the variable of interest (e.g., flow, pressure, etc.). Each drive controller may be set up by the user simply inputting a few values into the drive controller. Based on the inputs, the drive controllers may interpolate control points using an assumed linear relationship between the variable to be controlled (e.g., pressure) and the current driven to the pump. Feedback data from the system may be used to continually update the drive controllers so as to potentially allow them to better balance power usage to each pump.

Abstract: The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of ?4?7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.

Abstract: The system and methodology of the present invention employs available data obtained in connection with previous transactions to create one or more databases comprising feature sets which are used in transaction decision making solutions. The available data from previous transactions which is used in creating feature sets may include all available production data or the data may be stratified across specific industries and/or across specific decision support customers to optimize the expected decision making results. A feature engine is provided which uses a combination of data, time and combinational aggregate functions to feature engineer one or more feature sets used for one or more purposes, such purposes to include identity verification, fraud assessment, document verification as well as other assessments related to selectively permit or not permit transactions to proceed.

Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.